Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection

Medical Science Monitor

Volumn 10, Issue 12, 2004, Pages

  Tursi, Antonio ^a,e   Brandimarte, Giovanni ^b   Giorgetti, Gian Marco ^c   Modeo, Maria Ester ^d  

^a Lorenzo Bonomo Hospital   (Italy)

^b Cristo Re Hospital   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d POLICLINICO   (Italy)

^e NONE   (Italy)

Author keywords

Antibiotics; Helicobacter pylori; Probiotics; Proton pump inhibitors; Ranitidine bismuth citrate; Second line therapy; Treatment

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CARBON 13; ENTEROLACTIS; ESOMEPRAZOLE; PANTOPRAZOLE; PROBIOTIC AGENT; RANITIDINE; TINIDAZOLE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOSCOPY; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTRITIS; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LACTOBACILLUS CASEI; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; PEPTIC ULCER; SIDE EFFECT; TREATMENT FAILURE; TREATMENT WITHDRAWAL; UREA BREATH TEST; VOMITING;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTOBACILLUS CASEI; MALE; MIDDLE AGED; PROBIOTICS; TREATMENT FAILURE;

EID: 13944275586     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cammaroca G, Tursi A, Montalto M et al: Prevention and treatment of low-grade B-cell primary gastric lymphoma by anti-H. pylori therapy. J Clin Gastroenterol, 1995; 21: 118-22
2. Cammarota G, Tursi A, Montalto M et al: Clinical assessment of the relationship of H.pylori gastroduodenal pathologies: a prospective analysis of 228 consecutive patients. Panminerva Med, 1995; 37: 178-81
3. Mansour-Ghanaei F, Fallah MS, Shafaghi A: Eradication of Helicobacter pylori in duodenal ulcer disease; tetracycline & furazolidone vs. metronidazole & amoxicillin in omeprazole based triple therapy. Med Sci Monit, 2002; 8: PI27-PI30
4. Leung WK, Graham DY: Rescue therapy for Helicobacter pylori. Curr Treat Options Gastroenterol, 2002; 5: 133-38
5. Malfertheiner P, Megraud F, O'Morain C et al: EHPSG. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther, 2002; 16: 167-80
6. Cammarota G, Tursi A, Papa A et al: Sensitivity testing for Helicobacter pylori should be more widely available. BMJ, 1996; 343: 1079-80
7. Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F et al: The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. Med Sci Monit, 2003; 9(8): PI105-PI108
8. Zullo A, Hassan C, Campo SM et al: Triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther, 2001; 15: 1193-97
9. Tursi A, Brandimarte G, Giorgetti GM et al: Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin at first or second line therapy to cure Helicobacter pylori infection. Hepato-gastroenterol, 2002; 49: 1006-9
10. Sanders ME: Probiotics. Food Technology, 1999; 53: 67-77
11. Goossens D, Jonkers D, Stobberingh E et al: Probiotics in gastroenterology: indications and future perspectives. Scand J Gastroenterol, 2003; 38(Suppl.239): 15-23
12. Donaldson RM Jr, Toskes PP: The relationship of enteric bacterial population to gastrointestinal function and disease. In: Sleisenger MH, Fordtran JS, Eds. Gastrointestinal disease. New York, WB Saunders, 1989: 107-13
13. Kabir AMA, Aiba Y, Takagi A et al: Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut, 1997; 41: 49-55
14. Coconnier MH, Lievin V, Hemery E, Servin AL: Antagonistic activity against Helicobaderinfecuon in viiro and in vivo by the human Lactobacillus acidophilus Strain LB. Appl Env Microbiol, 1998; 64: 4573-80
15. Cats A, Kuipers EJ, Bosschaert MAR et al: Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther, 2003; 17: 429-35
16. Scholten T, Gatz G, Hole U: Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther, 2003; 18: 587-94
17. The European Helicobacter pylori Study Group: Current European Concepts in the management of Helicobacter pylori infection. Gut, 1997; 41: 8-13
18. Laine L, Estrada R, Trujillo M et al: Effect of proton-pump inhibitor therapy as diagnostic testing for Helicobacter pylori. Ann Intern Med, 1998; 129: 547-50
19. Canducci F, Armuzzi A, Cremonini F et al: A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther, 2000; 14: 1625-29
20. Cremonini F, Di Caro S, Covino M et al: Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol, 2002; 97: 2744-49
21. Tursi A, Cammarota G, Montalto M et al: Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. Aliment Pharmacol Ther, 1996; 10: 285-88
22. Tursi A, Cammarota G, Papa A et al: One-week low-dose triple therapy vs. two-week medium-dose therapy for H. pylori infection. Hepato-gastroenterol, 1996; 43: 859-62
23. Pipin GA, Wood JR: Ranitidine bismuth citrate. Drugs Today, 1997; 33: 431-51
24. McColm AA, McLaren A, Klinkert G et al: Ranitidine bismuth citrate: a novel anti-ulcer agent with different psycho-chemical characteristics and improved biological activity to a bismuth-citrate-ranitidine admixture. Aliment Pharmacol Ther, 1996; 10: 241-50
25. Dore MP, Sepulveda AR, Mura I et al: Explanation for variability of omeprazole-amoxycillin therapy? Tolerance of H. pylori to amoxicillin. Gastroenterology, 1997; 112: A105 (Abstract)
26. Harsch IA, Hahn EG, Konturek PC: Pseudomembranous colitis after eradication of Helicobacter pylori infection with a triple therapy. Med Sci Monit, 2001; 7: 751-54
27. Armuzzi A, Cremonini F, Bartolozzi F et al: The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther, 2001; 15: 163-69
28. Wendakoon CN, Fedio W, MacLeod A, Ozimek L: In vitro inhibition of Helicobacter pylori by dairy starter cultures. Milchwissenschaft, 1998; 53: 499-502